Colorectal cancer assay kit

biomarqueursFFPE tissuesclinical

1.A multiplexed test 2.Accuracy and reliability of the results 3.Low sample input Features 1. Simultaneous detection of seven monomorphic homopolymer biomarkersassessment 2. Fast results – 1 hourfrom sample to result 3. Evaluate results with the RapidSeq126®report software 4. Tested with paraffin-embedded samples This RapidSeq MSI Assay is a PCR-based melting detection assay intended to qualitative detect a novel panel of seven monomorphic homopolymer biomarkers (MRE11, SULF2, RYR3, SEC31A, BTBD7, ACVR2A, and DIDO1) in formalin-fixed, paraffin-embedded (FFPE) tissue sections from human cancer tissue clinical samples. The Assay based on RapidSeq® platform automates the entire process from nucleic acids are liberated from FFPE sample, PCR amplified and melting curve assay to report of MSI status in less than 1 hour. Biomarkers seven monomorphic homopolymer biomarkers: MRE11, SULF2, RYR3, SEC31A, BTBD7, ACVR2A, and DIDO1 Product Specifications Panel RapidSeq PHLOSS Assay of a novel panel of seven monomorphic homopolymer biomarkers Reactions 3 times/target for a sample Internal control housekeeping gene GAPDH Sample types paraffin-embedded samples Turnaround time —1hour from sample to answer To be used with RapidSeq126®Instrument Data analysis RapidSeq126®report software Scientific Background Determination of mismatch repair (MMR) and/or microsatellite instability (MSI) status in colorectal cancer (CRC) is recommended to aid in the identification of patients with Lynch syndrome or as a prognostic indicator. In addition, it is becoming increasingly important as predictive biomarker for cancer immunotherapy.